SUMMARY
In 1988 the uptake of hepatitis B immunization among trainees and consultants in accident and emergency (A&E) medicine was poor. Only 22% of senior registrars and 26% of consultants surveyed had been immunized. ' The main reasons for these low rates were unjustified fears about the safety of the plasma-derived vaccine then available and failure to accept that A&E staff were at risk. Concern was also expressed over rates of seroconversion and the degree of protection afforded by the vaccine.
In the six years since then there have been two major changes. Firstly, the development of a new, genetically engineered vaccine and, secondly, the publication of govemment guidelines which indicated that hospitals must have offerred immunization to all surgeons by the middle of 1994. Other health care workers engaging in 'exposure-prone procedures' should have been immunized by the following year.2
The present study was undertaken in 1993 to assess the current status among A&E practitioners with regard to uptake of the new vaccine and attitudes towards immunization in the light of these developments.
SUBJECTS AND METHODS
Early in 1993 a confidential questionnaire was sent to every member of the BAEM. Members were asked to indicate their present grade and hepatitis B immunization status. Those respondents who did not intend to become immunized against hepatitis B were asked to state the reasons behind this decision.
The immunization status of each respondent was classified into one of eight categories (Table 1) .
RESULTS
Seven hundred and forty two questionnaires were sent out and 406 were returned (55%). The results are summarized in Table 2 Vaccine safety
In 1988 the plasma-derived vaccine then available was (incorrectly) perceived as being unsafe. Since that time has been superceded by a genetically engineered vaccine. The 'S' gene, which codes for surface antigen, was first isolated in 1987. During manufacture of the vaccine the gene is inserted into a yeast host. The yeast cells multiply in a fermentation process and excess immunogenic surface antigen is produced, then separated and purified before being processed into vaccine. The previous plasma-derived vaccine was rendered safe only after an expensive purification process, whereas the new vaccine is widely accepted as being free of any infective hazard.
Adverse effects are protean, but generally minor, such as redness and soreness at the injection site, headache, abdominal upset, fever and rashes. Such hypersensitivity reactions are usually caused by the aluminium hydroxide adjuvant or the preservative rather than the surface antigen or yeast protein residue. Arthralgia, occasionally severe when associated with immune complex formation in subjects positive for HLA B27, may rarely occur.
Efficacy of vaccine
The new vaccine is extremely effective, the usual adult dosage schedule (for subjects less than 50 years old) of 20 pg intramuscularly repeated at 1 and 6 months produces protective antibody titres of greater than 100 mlu mL-1 in 86% of healthy subjects. Those who do not respond with this schedule may produce adequate antibody levels after one or two additional doses.1" The incidence of inadequate antibody response in the present survey (minimum 3.4%, maximum 4.3%) is similar to the previously reported range of 1-4%.12 Cost of pre-vaccination testing versus mass immunization 
